We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 311

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 10 2013

In November, the Supreme Court issued its decision in the sildenafil case, and, as part of its order, found the patent to be invalid. As this case was

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 3 2013

Bayer sought to prohibit the Minister of Health from issuing a Notice of Compliance to Cobalt for a generic version of Bayer’s oral contraceptive

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 27 2013

In this case, Apotex claimed damages pursuant to s. 8 of the NOC Regulations, and Pfizer alleged that Apotex should not be entitled to damages, due

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada, USA
  • -
  • May 22 2013

The Supreme Court has dismissed Eli Lilly of Canada Inc.’s leave on the issue, as summarized by the Court, as to whether the creation by the Federal

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 13 2013

This case involved a dispute over ownership and alleged infringement of copyright in a number of computer software programs. The Court held that the

Reynolds Presto Products Inc. v. P.R.S. Mediterranean Ltd., 2013 FCA 119

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 8 2013

The Court of Appeal has overturned a lower court decision and struck the mark NEOWEB from the register because it is confusing with the earlier

Teva Canada Innovation v. Attorney General of Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 8 2013

The governments of a number of provinces sought judicial review of a decision of the Copyright Board of Canada dismissing their objection that the

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the

NOC proceedings

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 25 2013

The Federal Court found Teva’s allegations of invalidity were not justified for Novartis’ narrow compound patent, while the allegations against